Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06514794 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
A Phase 2 study of Lymphoblastic Lymphoma and T-cell Acute Lymphoblastic Leukemia, sponsored by Wugen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 10
- Study locations
NCT06514794: Recruiting Phase 2 study of Lymphoblastic Lymphoma and T-cell Acute Lymphoblastic Leukemia, sponsored by Wugen.
NCT06514794 is a Phase 2 study of Lymphoblastic Lymphoma and T-cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Wugen. The registered enrollment target is 125 participants, below the 186-participant average among 21 other Lymphoblastic Lymphoma trials with a reported enrollment target (33% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06514794, a Phase 2 study of Lymphoblastic Lymphoma and T-cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Wugen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 10
- Study locations
Study Summary
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Primary Outcome
CRc is defined as proportion of patients that achieve a complete remission (CR) + CR with incomplete hematologic recovery (CRi)
Conditions Studied
Interventions
- BIOLOGICAL WU-CART-007
Study Locations (10)
California
- City of Hope - Duarte
- Children's Hospital Los Angeles - Los Angeles
Victoria
- Peter Mac Callum Cancer Institute - Melbourne
- Royal Children's Melbourne - Melbourne
Florida
- H. Lee Moffitt Cancer Center and Research Institute Hospital - Tampa
Missouri
- Washington University Saint Louis - St Louis
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-01-31 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 2 |
What NCT06514794 shows while recruiting
NCT06514794 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 186-participant average among 21 other Lymphoblastic Lymphoma trials with a reported enrollment target (33% lower).
The record links to 2 conditions, with Lymphoblastic Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which WU-CART-007 is the first listed.
NCT06514794 lists 10 locations in 8 states (California, Victoria, Florida).
Frequently Asked Questions
What is clinical trial NCT06514794 about?
NCT06514794 is a clinical study titled "A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)". The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
What is the current status of trial NCT06514794?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2025-01-31. Estimated completion is 2028-12-30.
What conditions does trial NCT06514794 study?
This clinical trial studies the following conditions: Lymphoblastic Lymphoma, T-cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT06514794?
The interventions under investigation include: WU-CART-007 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06514794?
This trial is sponsored by Wugen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06514794 being conducted?
This trial has 10 study locations across California, Florida, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoblastic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06514794's enrollment target sits among peer trials
125 10th of 21 higher than 12 of 21 other Lymphoblastic Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoblastic Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
RECRUITING · Phase 2
-
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
RECRUITING · Phase 2
-
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI